Literature DB >> 29405930

MeCP2 as an Activator of Gene Expression.

Patricia M Horvath1, Lisa M Monteggia2.   

Abstract

Rett syndrome is a neurodevelopmental disorder that primarily affects females and is caused by mutations in the methyl-CpG-binding-protein 2 (MECP2) gene. Initially, MeCP2 had been shown to be a repressor of gene transcription. In their 2008 paper, Chahrour and colleagues (DOI: 10.1126/science.1153252) reported that MeCP2 could also function as a transcriptional activator.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29405930      PMCID： PMC5909705          DOI： 10.1016/j.tins.2017.11.005

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN： 0166-2236            Impact factor:   13.837


  15 in total

1.  Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA.

Authors:  R R Meehan; J D Lewis; A P Bird
Journal:  Nucleic Acids Res       Date:  1992-10-11       Impact factor: 16.971

2.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription.

Authors:  P L Jones; G J Veenstra; P A Wade; D Vermaak; S U Kass; N Landsberger; J Strouboulis; A P Wolffe
Journal:  Nat Genet       Date:  1998-06       Impact factor: 38.330

3.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2.

Authors:  R E Amir; I B Van den Veyver; M Wan; C Q Tran; U Francke; H Y Zoghbi
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

4.  [On a unusual brain atrophy syndrome in hyperammonemia in childhood].

Authors:  A Rett
Journal:  Wien Med Wochenschr       Date:  1966-09-10

5.  Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain.

Authors:  Matthew Tudor; Schahram Akbarian; Richard Z Chen; Rudolf Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-13       Impact factor: 11.205

6.  A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases.

Authors:  B Hagberg; J Aicardi; K Dias; O Ramos
Journal:  Ann Neurol       Date:  1983-10       Impact factor: 10.422

7.  MeCP2 regulates activity-dependent transcriptional responses in olfactory sensory neurons.

Authors:  Wooje Lee; Jung-Mi Yun; Rima Woods; Keith Dunaway; Dag H Yasui; Janine M Lasalle; Qizhi Gong
Journal:  Hum Mol Genet       Date:  2014-07-09       Impact factor: 6.150

8.  An RNA interference screen identifies druggable regulators of MeCP2 stability.

Authors:  Laura M Lombardi; Manar Zaghlula; Yehezkel Sztainberg; Steven A Baker; Tiemo J Klisch; Amy A Tang; Eric J Huang; Huda Y Zoghbi
Journal:  Sci Transl Med       Date:  2017-08-23       Impact factor: 17.956

9.  MeCP2, a key contributor to neurological disease, activates and represses transcription.

Authors:  Maria Chahrour; Sung Yun Jung; Chad Shaw; Xiaobo Zhou; Stephen T C Wong; Jun Qin; Huda Y Zoghbi
Journal:  Science       Date:  2008-05-30       Impact factor: 47.728

10.  MeCP2 and histone deacetylases 1 and 2 in dorsal striatum collectively suppress repetitive behaviors.

Authors:  Melissa Mahgoub; Megumi Adachi; Kanzo Suzuki; Xihui Liu; Ege T Kavalali; Maria H Chahrour; Lisa M Monteggia
Journal:  Nat Neurosci       Date:  2016-09-26       Impact factor: 24.884
View more
  14 in total

1.  Variant Profile of MECP2 Gene in Sri Lankan Patients with Rett Syndrome.

Authors:  D Hettiarachchi; N F Neththikumara; B A P S Pathirana; V H W Dissanayake
Journal:  J Autism Dev Disord       Date:  2020-01

2.  Characterizing the phenotypic effect of Xq28 duplication size in MECP2 duplication syndrome.

Authors:  Sarika U Peters; Cary Fu; Bernhard Suter; Eric Marsh; Timothy A Benke; Steve A Skinner; David N Lieberman; Shannon Standridge; Mary Jones; Arthur Beisang; Timothy Feyma; Peter Heydeman; Robin Ryther; Walter E Kaufmann; Daniel G Glaze; Jeffrey L Neul; Alan K Percy
Journal:  Clin Genet       Date:  2019-03-15       Impact factor: 4.438

Review 3.  Soma-to-germline transformation in chromatin-linked neurodevelopmental disorders?

Authors:  Katherine M Bonefas; Shigeki Iwase
Journal:  FEBS J       Date:  2021-10-08       Impact factor: 5.622

Review 4.  Sex differences in Mecp2-mutant Rett syndrome model mice and the impact of cellular mosaicism in phenotype development.

Authors:  Mayara C Ribeiro; Jessica L MacDonald
Journal:  Brain Res       Date:  2020-01-02       Impact factor: 3.252

Review 5.  The role of nuclear Ca2+ in maintaining neuronal homeostasis and brain health.

Authors:  Pawel Mozolewski; Maciej Jeziorek; Christoph M Schuster; Hilmar Bading; Bess Frost; Radek Dobrowolski
Journal:  J Cell Sci       Date:  2021-04-22       Impact factor: 5.285

Review 6.  Patient-derived iPSC modeling of rare neurodevelopmental disorders: Molecular pathophysiology and prospective therapies.

Authors:  K R Sabitha; Ashok K Shetty; Dinesh Upadhya
Journal:  Neurosci Biobehav Rev       Date:  2020-12-25       Impact factor: 8.989

7.  Consequences of prenatal exposure to valproic acid in the socially monogamous prairie voles.

Authors:  L Sailer; F Duclot; Z Wang; M Kabbaj
Journal:  Sci Rep       Date:  2019-02-21       Impact factor: 4.379

8.  Brain-enriched microRNAs circulating in plasma as novel biomarkers for Rett syndrome.

Authors:  Kira Sheinerman; Aleksandra Djukic; Vladimir G Tsivinsky; Samuil R Umansky
Journal:  PLoS One       Date:  2019-07-10       Impact factor: 3.240

Review 9.  Proteomic and transcriptional changes associated with MeCP2 dysfunction reveal nodes for therapeutic intervention in Rett syndrome.

Authors:  Ketan Marballi; Jessica L MacDonald
Journal:  Neurochem Int       Date:  2021-05-26       Impact factor: 4.297

10.  Phenotypic features in MECP2 duplication syndrome: Effects of age.

Authors:  Sarika U Peters; Cary Fu; Eric D Marsh; Tim A Benke; Bernard Suter; Steve A Skinner; David N Lieberman; Shannon Standridge; Mary Jones; Arthur Beisang; Timothy Feyma; Peter Heydeman; Robin Ryther; Daniel G Glaze; Alan K Percy; Jeffrey L Neul
Journal:  Am J Med Genet A       Date:  2020-11-10       Impact factor: 2.802
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.